7Baggers
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.

Freeline Therapeutics Holdings plc
(NASDAQ:FRLN) 

FRLN stock logo

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is FLT180a, a gene therapy product cand...

Founded: 2015
Full Time Employees: 200
CEO: Anne Prener  
Sector: Healthcare
Industry: Biotechnology
Healthcare
Share this website to your friends
Freeline Therapeutics plc Days Payable Outstanding ttm (DPO)
202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 0278.09556.18834.261,112.351,390.441,668.531,946.61
Freeline Therapeutics plc Days Receivable Outstanding ttm (DSO)
202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 0263.59527.18790.761,054.351,317.941,581.531,845.11
Freeline Therapeutics plc Days Inventory Outstanding ttm (DIO)
202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 027.4654.9282.38109.83137.29164.75192.21
Freeline Therapeutics plc Op Cashflow Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -16.29-13.96-11.63-9.31-6.98-4.65-2.330
Freeline Therapeutics plc Free Cashflow Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -17.83-15.29-12.74-10.19-7.64-5.1-2.550
Freeline Therapeutics plc Cash Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 01.823.655.477.299.1210.9412.76
Freeline Therapeutics plc P/S ratio ttm
202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 06.8113.6220.4327.2434.0540.8747.68
Freeline Therapeutics plc (GAAP) P/E ratio ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -186.53-159.88-133.24-106.59-79.94-53.29-26.650
Freeline Therapeutics plc P/B ratio ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 045.2390.47135.7180.93226.17271.4316.63
No extra charts and metrics for this ticker.